Integra Connect to Share Study Results Underscoring the Importance of Early and Rapid Genetic Testing for Improved Survival Rates in Patients with Newly Diagnosed, Stage 4 Non-Small Cell Lung Cancer
The Floridant/10184742

Findings from the Integra Connect Database (ICD) Retrospective Observational Study to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting

WEST PALM BEACH, Fla., May 27, 2022 /PRNewswire/ -- Integra Connect, the leading provider of value-based, precision medicine solutions and services for specialty care, will present findings from a retrospective observational study in newly diagnosed, stage 4 non-small cell lung cancer (NSCLC) that demonstrates improved patient survival rates when molecular testing is applied prior to initiating treatment. The results will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4 at 1:15 p.m. CST. The abstract can be viewed online here.

More on The Floridant

• Terran Orbital Integrates CAPSTONE Aboard Rocket Lab Electron Rocket
• Bobby Nichols - Fiddlesticks Charity Foundation names 2022-2023 board of directors
• Ismail Sirdah' Guide To Landing Event Sponsorships
• Doral Chamber of Commerce Proudly Welcomes BroadMAX Networks as a Trustee
• Doral Chamber of Commerce Proudly Welcomes Hurricane Digital Marketing as a Trustee

The database analysis, which was supported by an unrestricted grant from Thermo Fisher Scientific, focused on 525 newly diagnosed stage 4 NSCLC patients harboring genetic mutations or actionable oncogenic drivers (AOD). The findings suggest that treatment outcomes were significantly compromised in patients (n=141) who initiated treatment (chemotherapy, immune checkpoint inhibitor, or both) before their AOD results were reported, compared to the control group of patients (n=384) who initiated treatment after receiving their AOD results.

---

Show All News | Report Violation